Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Economics of Cancer Care
Causes for Hospital Readmissions of Patients with Cancer
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
September 2013, Vol 4, No 7
>Chicago, IL—Hospitalizations and readmissions add substantial costs to healthcare. The annual cost of 30-day hospital readmissions in the United States is estimated to be $16 billion.
Read Article
Poor Adherence to Oral Cancer Drugs a Growing Concern
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
September 2013, Vol 4, No 7
Chicago, IL—The number of oral oncolytic drugs has increased dramatically, but despite increased convenience, there is growing concern regarding adherence, said Winson Y. Cheung, MD, MPH, Assistant Professor, University of British Columbia Division of Medical Oncology, Vancouver, at a session on adherence at ASCO 2013.
Read Article
Mammography Screening Rates Enhanced by Copay Elimination
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
September 2013, Vol 4, No 7
Removing copays may help boost mammography screening rates for all age-groups above age 40 years. One insurer found a significant increase in screening rates with the removal of a copay, said Jeffrey M. Peppercorn, MD, MPH, Medical Oncologist at Duke Cancer Institute, Durham, NC.
Read Article
Quality Measures, Pricing, and Policy Challenges in the Oncology Landscape
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
September 2013, Vol 4, No 7
Hollywood, FL—Seismic shifts in the oncology landscape have led to pricing and policy changes that affect the delivery of quality care in oncology, said Michael N. Dubroff, DO, FACOP, Senior Director, Payer Support for Genentech, who lent his perspective at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Balancing Cost and Quality in Oncology
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
September 2013, Vol 4, No 7
Hollywood, FL—The goal of balancing cost and quality leaves no stakeholder without a challenge, said Grant D. Lawless, MD, RPh, Director, Healthcare Decision Analysis Program, and Associate Professor of Clinical Pharmacy, University of Southern California, Los Angeles.
Read Article
Assessing the Value of New, Costly Radiation Therapies in Older Patients with Breast Cancer
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
July 2013, Vol 4, No 6
Chicago, IL—For-profit hospitals are more likely than their nonprofit counterparts to treat elderly patients with breast cancer with an expensive form of radiotherapy—despite lacking evidence of its benefit, researchers from the Yale Cancer Outcomes, Public Policy and Effectiveness Research Center reported at the 2013 American Society of Clinical Oncology annual meeting.
Read Article
Can We Afford to Make Progress in Cancer Care? The Economics of Drug Development
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
July 2013, Vol 4, No 6
Chicago, IL—The rapid advances in cancer treatment, especially in personalized medicine, are occurring at an enormous financial cost to the healthcare system.
Read Article
ASCO President Highlights Bridges to Conquer Cancer
By
Wayne Kuznar
Economics & Value
,
Economics of Cancer Care
July 2013, Vol 4, No 6
Chicago, IL—“Building Bridges to Conquer Cancer” was the theme of the 2013 American Society of Clinical Oncology (ASCO) annual meeting, as well as of the address of ASCO’s outgoing President Sandra M. Swain, MD.
Read Article
Nearly 1 in 5 Patients with Cancer Reports Financial Distress
By
Audrey Andrews
Economics & Value
,
Economics of Cancer Care
July 2013, Vol 4, No 6
Financial distress is prevalent among insured patients with cancer, and although most patients state a desire to talk to their physicians about costs, this discussion rarely occurs, according to a study conducted at Duke University Medical Center, Durham, NC.
Read Article
Off-Label Drug Use in Oncology Accounts for 18% of Spending
By
Caroline Helwick
Economics & Value
,
Economics of Cancer Care
June 2013, Vol 4, No 5
An examination of the Surveillance, Epidemiology and End Results (SEER)-Medicare database from 1998 to 2008 revealed that a significant number of patients with cancer receive drugs that are neither indicated by the US Food and Drug Administration (FDA) for the specific condition nor endorsed by the National Comprehensive Cancer Network (NCCN) compendia—and 18% of the spending on cancer drugs is for off-label drug use.
Read Article
Page 7 of 9
1
2
3
4
5
6
7
8
9
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma